Claims
- 1. A compound of formula I:
- 2. A compound of formula I according to claim 1, wherein
m is 3, l and n each denote 0 or 1, and l+n is 1.
- 3. A compound of formula IA:
- 4. 3′-n-Propyl-4′-[2-(3-hydroxyphenoxy)-ethoxy]-1,1′-biphenyl-4-carboximidamide-O-β-D-glucuronide.
- 5. 3′-n-Propyl-4′-[2-(3-hydroxyphenoxy)-ethoxy]-1,1′-biphenyl-4-carboximidamide-O-glucose.
- 6. A process for preparing a compound of formula I according to claim 1, wherein a hydroxybenzamidine of formula II,
- 7. A process according to claim 6, wherein the reaction is carried out in the presence of an acid catalyst or a Lewis acid.
- 8. A process according to claim 6, wherein the reaction is carried out in the presence of a basic transition metal compound.
- 9. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier and/or excipient.
- 10. A method of treating a disease that is responsive to LTB4-antagonistic activity comprising administering to a host need thereof a therapeutically effective amount of one or more compounds according to claim 1 or the stereoisomers thereof or the acid addition salts thereof.
- 11. A method of preventing a disease that is responsive to LTB4-antagonistic activity comprising administering to a host need thereof a therapeutically effective amount of one or more compounds according to claim 1 or the stereoisomers thereof or the acid addition salts thereof.
- 12. A method according to claim 10, wherein the disease that is treated is selected from arthritis, asthma, chronic obstructive pulmonary disease, psoriasis, ulcerative colitis, gastro- or enteropathy induced by nonsteroidal antiphlogistics, cystic or pulmonary fibrosis, Alzheimer's disease, shock, reperfusion damage/ischaemia, atherosclerosis, multiple sclerosis, autoimmune diseases, malignant neoplasia, alveolitis.
- 13. A method according to claim 11, wherein the disease that is prevented is selected from arthritis, asthma, chronic obstructive pulmonary disease, psoriasis, ulcerative colitis, gastro- or enteropathy induced by nonsteroidal antiphlogistics, cystic or pulmonary fibrosis, Alzheimer's disease, shock, reperfusion damage/ischaemia, atherosclerosis, multiple sclerosis, autoimmune diseases, malignant neoplasia, alveolitis.
Priority Claims (1)
Number |
Date |
Country |
Kind |
100 52 658.6 |
Oct 2000 |
DE |
|
RELATED APPLICATIONS
[0001] Benefit of U.S. Provisional Application Serial No. 60/250,661, filed on Dec. 1, 2000 is hereby claimed, and said Application is herein incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60250661 |
Dec 2000 |
US |